The emergence and spread of drug-resistant bacteria is an important health and socioeconomic threat with global dimensions, which is developing towards an emergency/pandemic crisis. No drugs are available to address the disease, and diagnostic tools are poorly effective. This negatively impacts the treatment and survival of critically ill patients and drug-resistant bacteria may spread outside hospital settings, representing a critical risk for the global population. This COST Action will bring together industrial and academic European scientists with different skills and expertise in a multidisciplinary and concerted initiative. The Action will combine disciplines such as chemistry, physics, bioinformatics, genetics, biology, immunology, and medicine in understanding the genetic and molecular bases of bacterial drug resistance, developing innovative diagnostic tools, and delivering lead/pre-clinical candidates, antibody-based therapies, and clinical-ready repurposed drugs towards the personalized treatment of drug-resistant bacterial infections.
Funding source: H2020 COST-Action
Working Group member of CECAV: Patrícia Poeta (WG1, WG2).
Link: Action CA21145
